Cargando…
Treatment options for vasomotor symptoms in menopause: focus on desvenlafaxine
Vasomotor symptoms (VMS), including hot flashes and night sweats, occur in as many as 68.5% of women as a result of menopause. While the median duration of these symptoms is 4 years, approximately 10% of women continue to experience VMS as many as 12 years after their final menstrual period. As such...
Autores principales: | Umland, Elena M, Falconieri, Laura |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3410701/ https://www.ncbi.nlm.nih.gov/pubmed/22870045 http://dx.doi.org/10.2147/IJWH.S24614 |
Ejemplares similares
-
Treatment Strategies for Reducing the Burden of Menopause-Associated Vasomotor Symptoms
por: Umland, Elena M.
Publicado: (2008) -
The role of transdermal estrogen sprays and estradiol topical emulsion in the management of menopause-associated vasomotor symptoms
por: Egras, Amy M, et al.
Publicado: (2010) -
Is Desvenlafaxine Effective and Safe in the Treatment of Menopausal Vasomotor Symptoms? A Meta-analysis and Meta-regression of Randomized Double-blind Controlled Studies
por: Berhan, Yifru, et al.
Publicado: (2014) -
Management of menopause-associated vasomotor symptoms: Current treatment options, challenges and future directions
por: Pachman, Deirdre R, et al.
Publicado: (2010) -
Venlafaxine and desvenlafaxine in the management of menopausal hot
flashes
por: Johnson, Emily D, et al.
Publicado: (2011)